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Objective: To clarify issues regarding the frequency, prevention, outcome, and treatment of
patients with ventilator-associated tracheobronchitis (VAT), which is a lower respiratory tract
infection involving the tracheobronchial tree, while sparing the lung parenchyma.
Methods: We performed a systematic review and meta-analysis of relevant available data,
gathered though searches of PubMed, Scopus, and reference lists, without time restrictions.
A conservative random effects model was used to calculate pooled odds ratios (OR) and 95%
confidence intervals (CI).
Results: Out of the 564 initially retrieved articles, 17 papers were included. Frequency of VAT
was 11.5%. Selective digestive decontamination was not proved an effective preventive
strategy against VAT (OR: 0.62, 95% CI: 0.31e1.26). Presence, as opposed to the absence, of
VAT was not associated with higher attributable mortality (OR: 1.02, 95% CI: 0.57e1.81).
Administration of systemic antimicrobials (with or without inhaled ones), as opposed to
placebo or no treatment, in patients with VAT was not associated with lower mortality (OR:
0.56, 95% CI: 0.27e1.14). Most of the studies providing relevant data noted that administration
of antimicrobial agents, as opposed to placebo or no treatment, in patients with VAT was asso-
ciated with lower frequency of subsequent pneumonia and more ventilator-free days, but
without shorter length of intensive care unit stay or shorter duration of mechanical ventilation.e of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. Tel.: þ30 694
(M.E. Falagas).
9 Elsevier Ltd. All rights reserved.
326 M. Agrafiotis et al.Conclusions: Approximately one tenth of mechanically ventilated patients suffer from VAT.
Antimicrobial treatment of patients with VAT may protect against the development of subse-
quent ventilator-associated pneumonia and improve weaning outcome.
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Lower respiratory tract infections are an important cause of
morbidity and mortality in critical care patients.1 The respi-
ratory tract represents an anatomical continuum that
includes themouth and the nose, the oropharynx, the larynx,
the tracheobronchial tree and, finally, the lung parenchyma.
An impressive array of defensemechanisms, bothmechanical
(anatomical barriers, cough reflex, mucociliary clearance)
and immunological (cell-mediated and humoral), serves to
protect the lower respiratory tract from microbial invasion.
Institution of invasive mechanical ventilation may cause
a disruption in the defensive mechanisms predisposing to
lower respiratory tract colonization and subsequent infec-
tion, most notably, ventilator-associated pneumonia (VAP).2
Although VAP is in the centre of scientific investigation for
several years, especially as concerns to its potential
preventive measures,3,4 much less attention had been given
to ventilator-associated tracheobronchitis (VAT); namely, to
the lower respiratory tract infection involving the conduct-
ing zone of the lung (i.e. the tracheobronchial tree), but
sparing the gas exchange zone (i.e. lung parenchyma). This
fact may be attributed to the reluctance of many authoritiesto consider VAT as an independent clinical entity.5 Thus,
clinical data on VAT from well designed studies were not
available in the literature until fairly recently.5 However,
during the last years, VAT concentrated the interest of both
clinicians and researchers. For instance, in themost recently
published (2005) guidelines by the American Thoracic
Society and the Infectious Disease Society of America on
health-care associated pneumonia, VAT is regarded as
a cause of lower respiratory tract infection and an alterna-
tive diagnosis for patients with VAP.1
Given the augmenting interest on VAT, we endeavoured
to clarify issues regarding the frequency, prevention,
outcome, and treatment of patients with VAT, by per-
forming a systematic review and meta-analysis of the
available relevant data.Methods
Search strategy
Two reviewers (MA and IIS) independently performed the
literature search, study selection, and data extraction. Any
Prevention and treatment of VAT 327disagreement between the two reviewers was resolved by
consensus in meetings of all authors. We searched PubMed
and Scopus databases up to September 2008 using the
following key terms: (ventilator OR nosocomial ) AND
(tracheobronchitis OR bronchitis). We also hand searched
the reference lists of the initially retrieved papers and of
relevant review articles. No restriction was set regarding
the time of publication. Only papers in English were
included. Abstracts presented in international conferences
were not searched.
Study selection and data extraction
A paper was considered eligible for inclusion in our
systematic review if it reported on the frequency, preven-
tion, outcome, or treatment of patients with VAT. Case-
reports, laboratory/experimental studies, and studies on
neonatal/pediatric populations were omitted. The
following data were extracted from each study: first
author, year of publication, study setting and design,
number and demographics of participants, implicated
pathogens and method of microbiological confirmation,
frequency of VAT, length of intensive care unit (ICU) stay,
duration of mechanical ventilation, preventional or thera-
peutic interventions, mortality of patients with VAT, and
frequency of subsequent VAP.
Definition of VAT
VAT was defined based on the individual clinical and labo-
ratory criteria employed by the authors of the selected
papers; i.e. fever, increased volume and purulence of
secretions, a positive culture (quantitative or semi-
quantitative) of a respiratory sample (tracheal aspirates or
bronchoscopic specimens), and the absence of a new or an
evolving pulmonary infiltrate in the chest x-ray in a patient
on mechanical ventilation >48 hours.
Statistical methods and data analysis
Review Manager (RevMan; Copenhagen: Nordic Cochrane
Center, Cochrane Collaboration) was used for the statistical
analysis. Heterogeneity among the results of the selected
papers was evaluated by using both the I2-statistic and the
chi-squared test; a p value< 0.1 was considered statisti-
cally significant in the assessment of heterogeneity. Pooled
odds ratios and 95% confidence intervals were calculated by
employing the conservative DerSimonian-Laird random
effects model.Results
Characteristics of the selected articles
In Fig. 1 we present a flow diagram detailing the process we
employed to locate the potentially relevant articles. Out of
564 articles, which were retrieved from PubMed, Scopus,
and reference lists, 176,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22
papers, involving 7056 patients, fulfilled the inclusion
criteria of this systematic review. In detail, we identified10 randomized controlled trials (RCTs), 5 cohorts, and 2
case control studies. We should mention that all patients
included in a case control study by Nseir et al.7 were also
studied in a prospective observational cohort by the same
authors,10 accounting for 5% of the total population. In
addition another case control study by Nseir et al.8
recruited patients during the same time period with the
previous two studies.7,10 Characteristics and outcome data
of the included reports are presented in Tables 1e3.
Frequency of VAT
Based on five6,9e12 eligible reports which provided relevant
information, VAT affected 386 (11.5%) out of 3,362.
Methods of microbiologic diagnosis
In 16 of the included studies the authors used tracheal
aspirates for the microbiological diagnosis of VAT.6e10,12e22
Bronchoscopic cultures (bronchoalveolar lavage and pro-
tected specimen brush) have additionally been employed in
5 studies.9,13,15,16,19 Cultures were quantitative in 10
studies 7e10,13e15,19e21 and semiquantitative in 1 study.17 In
the 6 remaining studies6,11,16,18,20,22 the type of culture was
not reported. Regarding quantitative cultures of tracheal
aspirates, the selected cutoff point of bacterial concen-
tration for positivity was 106 cfu/ml in 6 studies,7,8,10,14,15,21
105 in 2 studies,9,13 103 cfu/ml in 1 study19 and 102 cfu/ml in
one study.20 While, cut- off points for quantitative cultures
of bronchoalveolar lavage and protected specimen brush
were 104 cfu/ml13,15 and 103 cfu/ml9,13,15,19 respectively.
Implicated pathogens in episodes of VAT
Out of the 176e22 reports included in this review, four studies
provided data on the microbial causes of VAT.9,10,21,22We
should mention that all these studies employed quantitative
cultures of tracheal aspirates9,10,21,22 or protected specimen
brush9 for the microbiological diagnosis of VAT. Gram-nega-
tive pathogens were the most common causes of VAT,
accounting for 75% (278 out of 369) of the isolates, while the
remaining 25% (91 out of 369) of the isolates were Gram-
positive. In detail, Pseudomonas aeruginosa (27%), Acineto-
bacter spp (18%) and methicilin-resistant Staphylococcus
aureus (14%) were the most frequently encountered patho-
gens in patients with VAT. Other culprit microorganismswere
methicilin-susceptible Staphylococcus aureus (6%), Klebsi-
ella spp. (5%), Escherichia coli (5%), Enterobacter spp. (4%),
Serratia spp. (4%), Streptococcus pneumoniae,Haemophilus
influenzae, and Moraxella catarrhalis.10,21,22 In addition,
Haemophilus influenzae, andMoraxella catarrhaliswere the
most common pathogens in the report by Buza et al.9 In
almost 21% of VAT episodes, the cause of VAT was
polymicrobial.9,10,21
Prevention
Eight eligible studies13e20 evaluated various strategies for
the prevention of VAT (Table 2). Selective digestive tract
decontamination (SDD) (5 RCTs),16e20 automatic regulation
of tracheal cuff pressure (one study),13 oral cavity
Figure 1 Flow diagram of the reviewed articles.
328 M. Agrafiotis et al.decontamination (one study),14 and the presence of
bacterial filter in the ventilator circuit (one study)15 were
the studied interventions.
Five16e20 RCTs evaluated the impact of SDD on the
incidence of VAT. Application of SDD as opposed to placebo,
standard or no treatment does not seem to reduce VAT
frequency (OR: 0.62, 95% CI: 0.31e1.26) (Fig. 2).
Similarly, employment of automatic regulation of
tracheal cuff pressure,13 oral cavity decontamination,14 or
bacterial filter in the ventilator circuit15 in mechanicallyventilated patients was not associated with lower
frequency of VAT than comparators (data shown in Table 2).Outcome of patients with VAT
Crude and attributable mortality
Out of the 176e22 articles included in the present review,
four7e10 studies reported data on the mortality of patients
with VAT. Based on the data provided by the two case
Table 1 Cohorts, case control and series reporting on ventilator-associated tracheobronchitis.
First author
[ref]
Year of
publication/
Country
Setting Study design/
Number of pts
Study Population Number of
patients
with VAT
(%)
Cultures
required for
confirmation
of diagnosis of
VAT
Pathogens Outcome
ICU LOS
(days)
MV
duration
(days)
Mortality
n/N (%)
Evolution
to VAP
n/N (%)
1 Weiss[6] 2006/
Germany
Surgical ICU Retrospective
cohort/60
Patients with
tertiary
peritonitis on MV
22/60 (37) Quantitative;
specimens
obtained
by tracheal
aspirates,
NR NR NR NR NR
2 Nseir[7] 2005/
France
General ICU Retrospective
matched
case-control/928
Patients without
chronic airway
disease on
MV>48 hours
70 (8) Quantitative;
specimens
obtained
by tracheal
aspirates
P.aeruginosa 30/86 (34) 28.0 15.7
24.5 (5e95)a,c
21.6 16.0
17 (3e95)a,c 16/55 (29)a,c
7/70 (10)
A.baumanni 16/86 (18)
Serratia spp 6/86 (6)
Other Gram (-) 14/86 (16)
MRSA 10/86 (11)
MSSA 5/86 (5)
S.pneumoniae 5/86 (5)
3 Nseir[8] 2004/
France
General ICU Prospective
matched
case-control/1259
COPD patients
on MV>48 hours
103 (8) Quantitative;
specimens
obtained
by tracheal
aspirates
P.aeruginosa 32/120 (27) 27.0 13.1
25 (9e60)b,c
21.5 12.0
20 (5e50)b,c
33/81 (41)b,c 11/103 (11)
A.baumannii 7/120 (4)
Enterobacter spp 7/120 (4)
Other Gram (-) 23/120 (19)
MRSA 19/120 (16)
MSSA 6/120 (0.5)
S.pneumoniae 4/120 (0.3)
4 Bouza [9] 2003/
Spain
Cardiac
surgical
ICU
Prospective
cohort/356
Patients
undergoing
cardiac surgery
29 (8) Quantitative;
specimens
obtained
by tracheal
aspirates, PSB,
H.influenzae 9/29 (31) 12 54 NR 6/29 (21) 5/29 (17)
M.catarrhalis 2/29 (7)
Other Gram (-) 4/29 (14)
S.pneumoniae 1/29 (3)
S.aureus 1/29 (3)
Polymicrobial 10/29 (34)
Negative 2/29 (7)
5 Nseir[10] 2002/
France
Medical-surgical
ICU
Prospective
cohort /2128
Patients on
MV>48 hours
201 (9) Quantitative;
specimens
obtained
by tracheal
aspirates
P.aeruginosa 72/251 (29) Surgical:
39.2 32
31(10e148)
Medical:
33.4 20.9
28.5(5e110)
Surgical:
32.2 31.1
23(3e132)
Medical:
26.0 17.1
22.5(5e193)
Surgical:
20/36
(56)
Medical
64/165
(39)
Total:
84/201
(42)
Surgical: 3/36 (8)
Medical 15/165 (9)
Total: 18/201 (9)
A.baumannii 61 /251 (24)
Klebsiella spp 30/251 (12)
Other Gram (-) 53/251 (21)
MRSA 38/251 (15)
MSSA 8/251 (3)
S.pneumoniae 9/251 (3)
6 Humphrey [11] 1987/USA Surgical ICU Prospective
cohort/24
Intubated
patients
with nosocomial
sinusitis
8 (33) NR NR NR NR NR NR
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330 M. Agrafiotis et al.control studies7,8 , both of which excluded patients who
eventually developed VAP, it was found that the presence,
as opposed to the absence, of VAT was not associated with
higher attributable mortality (OR: 1.02, 95% CI: 0.57e1.81)
(Fig. 3). While in the observational cohort by Nseir et al,
crude mortality was significantly higher in VAT patients, but
this difference did not persist when patients who subse-
quently developed VAP were excluded.10 Last, in the report
by Buza et al, in which patients who also developed VAP
were not excluded, crude mortality of VAT was significantly
higher compared to noncolonized patients.9
Length of ICU stay and duration of mechanical
ventilation
Data on the length of ICU stay and the duration of
mechanical ventilation were given by four7e10 of the
included in our review reports. One9 of these four7e10
studies failed to establish a statistically significant differ-
ence between patients with VAT and patients without VAT
with regard to the above outcomes (namely, length of ICU
stay and duration of mechanical ventilation). In contrast,
the remaining three7,8,10 studies revealed that patients
with VAT experienced longer ICU stay and more prolonged
mechanical ventilation compared to patients without VAT.Treatment of patients with VAT
Treatment modalities
In some of the included studies,7,8,10,21 patients with VAT
were treated with antimicrobial agents administered
systemically. A combination of systemic and inhaled anti-
microbials was given in one study.22
Impact of antimicrobial treatment on mortality of
patients with VAT
Data on the impact of the administration of systemic (with
or without inhaled) antimicrobials on the mortality of
patients with VAT were available for three10,21,22 [one
observational cohort10 and two RCTs21,22] of the eligible
studies. Administration of antimicrobials as opposed to
placebo or no treatment in patients with VAT was not found
to be associated with lower mortality (OR: 0.56, 95% CI:
0.27e1.14) (Fig. 4).Impact of antimicrobial treatment on the length of ICU
stay, the duration of mechanical ventilation, and the
number of ventilator-free days in patients with VAT
Out of the 17 studies6e22 included in our review, four7,8,10,21
studies provided information regarding the impact of anti-
microbial treatment on the length of ICU stay and the
duration of mechanical ventilation in patients with VAT.
Three7,10,21 of them did not demonstrate any statistically
significant benefit from antimicrobial treatment, as
opposed to placebo or no treatment, for patients with VAT.
In contrast, the remaining study (a case control study
involving patients with underlying chronic obstructive
pulmonary disease)8 noted that individuals with VAT
receiving antimicrobials experienced shorter length of ICU
stay and shorter duration of mechanical ventilation than
non-recipients.
Table 2 Randomized controlled trials on the prevention of ventilator-associated tracheobronchitis.
First author /[ref] Year of
publication/
Country
Setting Patient
population
Study
design/
Number of
enrolled pts
Cultures
required
for confirmation
of diagnosis of VAT
Intervention Randomization/
number
of patients
VAT incidence
n/N (%)
1 Valencia [13] 2007/Spain Medical-
respiratory
ICU
Patients on
MV with
anticipated
length of
stay>48 hours
142 Quantitative;
specimens
obtained by
tracheal aspirates,
PSB, BAL
Automatic cuff pressure
regulation
vs.
Conventional cuff
pressure regulation
Treatment
arm/73
Treatment
arm: 6 (8)
Control
arm/69
Control
arm: 7(10)
2 Fourrier [14] 2005/France General
ICU
Patients on
MV with
anticipated
length of
stay>5 days
227 Quantitative;
specimens
obtained by
tracheal aspirates
Oral decontamination
with chlorexidine gel
vs.
Placebo
Treatment
arm/ 113
Treatment
arm: 1/113 (1)
Placebo arm/114 Placebo
arm: 5/114 (4)
3 Lorente[ 15] 2003/Spain Medical-
surgical
ICU
Patients on
MV>24 hours
230 Quantitative;
specimens
obtained
by tracheal
aspirates,
PSB, BAL
Bacterial filter in the
ventilator circuit
vs.
No bacterial filter in
the ventilator circuit
Treatment
arm/114
Treatment
arm: 12/114 (11)
Control
arm/116
Control
arm: 9/116 (8)
4 Gastine [16] 1992/France General
ICU/
Patients on
MV>48 hours
445 NR; specimens
obtained
by tracheal
aspirates, PSB
Oral tobramycin, colisitn
and amphotericin B
vs.
Placebo.
Treatment
arm/220
Treatment
arm: 3/220 (1)
Placebo
arm/225
Placebo
arm: 6/225 (6)
5 Hammond [17] 1992 General
ICU
Patients on
MV>48
hours with
anticipated
length
of stay> 5 days
239 Semi quantitative;
specimens
obtained by
tracheal
aspirates
Intravenous cefotaxime for
the first 72 hours
plus oral gentamycin,
polymyxin, nystatin for
the whole length of stay
vs.
Intravenous cefotaxime
for the first 72 hours
Treatment
arm/114
Treatment
arm: 17/114 (15)
Control
arm/125
Control
arm: 20/125 (16)
6 Aertds [18] 1991/Denmark General
ICU/
Patients with
anticipated
length of
MV>5 days
56 NR; specimens
obtained
by tracheal
aspirates
Intravenous cefotaxime
plus Oral polymyxin E,
amphotericin B, norfloxacin
vs.
Standard care
Treatment
arm/17
Treatment
arm: 1/17 (6)
Control
arm/39
Control
arm: 17/39 (44)
(continued on next page)
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332 M. Agrafiotis et al.With respect to the impact of antimicrobial treatment
on the number of ventilator-free days, two21,22 of the
selected reports (both RCTs) provided relevant data. One
study21 showed that administration of antimicrobials
compared to placebo or no treatment in patients with VAT
was associated with more ventilator-free days; in the
second RCT (which included also patients with VAP) there
was a tendency towards more ventilation free days in the
treated group which however did not reach statistical
significance.22Impact of antimicrobial treatment on the rate of
progression to VAP
Data on the impact of antimicrobial treatment on the rate
of progression to VAP were available for three eligible
reports.10,21,22 While one observational study10 did not
establish any association between antimicrobial treatment
of patients with VAT and the rate of subsequent VAP, the
remaining two studies (in fact RCTs)21,22 showed that
frequency of subsequent VAP was lower in patients with
VAT receiving antimicrobial agents compared to placebo or
no treatment.
Discussion
By accumulating and critically appraising data from 7056
patients enrolled in 17 reports, we endeavoured to shed
light on various issues of VAT. The frequency of VAT is
estimated to be approximately 11.5%. Pseudomonas aeru-
ginosa, Acinetobacter spp and methicilin-resistant Staphy-
lococcus aureus are the most commonly implicated
pathogens; infection can be polymicrobial. SDD does not
seem to influence VAT frequency. Presence, as opposed to
absence, of VAT may not be associated with higher attrib-
utable mortality. Treatment of subjects with VAT with
antimicrobials may not improve mortality, length of ICU
stay or duration of mechanical ventilation, but it is asso-
ciated with lower frequency of subsequent VAP and prob-
ably a longer ventilation-free period.
The working definition of VAT is based on the presence of
fever, purulent secretions, microbiologically positive
samples obtained from the respiratory tract, and the
absence of significant findings in the chest radiography.1
This definition, however, has not yet been validated and
has been the subject of controversy, related to the
moderate sensitivity of chest x-ray in detecting pulmonary
infiltrates.23 Thus, it is quite possible that some of the
patients considered to have VAT, based on the absence of
pulmonary infiltrates on chest x-ray, may actually prove to
suffer from VAP if more sophisticated imaging techniques,
as computerized tomography, are employed.
VAT is considered a part of the spectrum of lower
respiratory tract infections, being an intermediate stage
between colonization and VAP.5 We should note that both
entities presumably share similar pathogenetic mecha-
nisms, including bypassing of the anatomical barriers and
cough reflex by the endotracheal tube, colonization of the
oropharynx and the stomach by pathogenic organisms with
subsequent micro- and macroaspirations and contamination
of respiratory care equipment. However, it is not clear
whether VAT should be regarded a unique clinical entity,
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Prevention and treatment of VAT 333distinct from other lower respiratory tract infections (most
importantly VAP) with its own clinical course and outcome.
Nevertheless, evidence from post-mortem studies does
suggest that respiratory tract bacterial infection may
involve the airways, causing inflammatory changes, while
sparing in the same time the lung parenchyma.24
Quantitative cultures of tracheal aspirates or bron-
choscopic specimens are used by most of the authors of
the included papers for the microbiological diagnosis of
VAT. However, the ideal respiratory sample and microbi-
ological method for VAT diagnosis has yet to be estab-
lished. Gram stain data (i.e the presence bacteria and
neutrophil polymorphonuclears in the smear) in combina-
tion with quantitative cultures of tracheal aspirates might
prove very useful in establishing the diagnosis of bronchial
infection and ruling out colonization.25 On the other hand
the role of bronchoscopic specimens, notably bron-
choalveolar lavage and protected specimen brush, for VAT
diagnosis remains controversial.25 We should note that
bronchoalveolar lavage sampling is performed by wedging
the bronchoscope into a subsegmental bronchus, followed
by introduction and retrieval of several boluses of normal
saline and is considered a method of choice for the
microbiological diagnosis of VAP.1,26 However since the
first aliquot essentially samples the bronchial region,
many investigators choose to disregard it or analyze it
separately in cases of suspected bronchial inflammation.26
From this point of view, the comparison of bacterial
counts between the first and subsequent aliquots might
become a very powerful toll for the microbiological diag-
nosis of VAT.
In the present systematic review the frequency of VAT
was estimated to be approximately 11.5%. Taking into
account the higher incidence of VAP in critically ill
patients,2 one might infer that VAT should not be an
obligatory intermediate stage preceding VAP. However,
whether VAT represents an additional risk factor for VAP
remains to be answered. From this point of view and though
VAT per se does not seem to influence mortality of
mechanically ventilated patients the importance of infec-
tion control measures and effective preventive strategies
must be underscored. None of the studies that evaluated
various prevention strategies, including SDD has shown
a reduced frequency for VAT. We should mention that our
results contrast to those of a previous meta-analysis
assessing the impact of SDD on VAT prevention.27
On the other hand, the findings of this present system-
atic review suggest, that if a patient fulfils the criteria
entailed in the working definition of VAT, they may indeed
benefit from antimicrobial treatment in terms of higher
number of ventilator-free days and a shorter rate of
subsequent VAP development. Of particular interest are the
results of the two therapeutic RCTs21,22 included in the
present review (Table 3). The findings from the trial by
Nseir et al suggest that systemic antibiotic treatment may
avert subsequent progression to VAP.21 Also, in the placebo
controlled study by Palmer et al,22 the addition of inhaled
to systemic antimicrobial treatment was evaluated in
patients with VAT; it should be noted however that in this
study ‘‘most’’ of the patients also had concurrent VAP and
the definition of VAT is based on the quantity of tracheo-
bronchial secretions collected over a predefined time
Study or Subgroup
Aerdts 1991
Gastine 1992
Hammond 1992
Rodirguez-Roldan 1990
Unertl 1987
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.17; Chi² = 5.38, df = 4 (P = 0.25); I² = 26%
Test for overall effect: Z = 1.32 (P = 0.19)
Events
1
3
17
3
3
27
Total
17
220
114
13
19
383
Events
17
6
20
3
5
51
Total
39
225
125
15
20
424
Weight
9.7%
19.0%
43.2%
12.7%
15.5%
100.0%
M-H, Random, 95% CI
0.08 [0.01, 0.67]
0.50 [0.12, 2.04]
0.92 [0.46, 1.86]
1.20 [0.20, 7.31]
0.56 [0.11, 2.77]
0.62 [0.31, 1.26]
Treatment Control Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours SDD Favours control
Figure 2 Effect of selective digestive tract decontamination on the incidence of ventilator-associated tracheobronchitis.
334 M. Agrafiotis et al.interval. Nevertheless, in this study, none of VAT-only
patients who received inhaled antimicrobials progressed to
VAP.22 Thus, treatment of VAT with systemic (with or
without inhaled) antimicrobials might be an additional
effective measure for preventing VAP and improving
patient outcomes. However the effectiveness of such
a strategy strongly depends upon employing reliable
microbiological criteria for the diagnosis of VAT and the
exclusion of VAP and colonization.25 We should also
mention that a potential role of inhaled antimicrobials in
the preventing28,29 and treating30,31 VAP has also been
elucidated in recent reviews and meta-analyses.
Since antimicrobial treatment of VAT has the potential
to reduce the rates of conversion to VAP, it is intuitively
plausible to expect that this effect may also be reflected in
the crude mortality rate of patients with VAT. This notion is
not supported by the results of our meta-analysis, although
there seems to be a tendency for a better outcome in the
treated group.Figure 3 Ventilator-associated trach
Figure 4 Effect of antimicrobial treatment on the crudeSeveral limitations of our study deserve consideration.
Firstly, as expected, therewere differences in the diagnostic
criteria for VAT employed by the authors of several eligible
papers, while these criteria were not specified at all in other
papers. In addition, the possibility of colonization cannot be
completely ruled on the basis of the current definition of
VAT. Also, differences exist regarding the type of sample and
the method of microbiological diagnosis employed by the
authors of the selected papers. For these reasons, the exact
approximation of VAT frequency and outcome might be not
completely accurate. Secondly, some of the included papers
were published before 2000 and, thus, their findings, might
not be relevant to modern practice. In addition, some of the
selected studies were not originally designed to assess issues
of VAT. Also, the mortality rates reported by the relevant
studies might be influenced by the inclusion of patients with
VAP in the studied population either as a result of the study
design22 or due to biases related to the interpretation of
chest radiography for the diagnosis of VAT in the ICUeobronchitis attributable mortality.
mortality of ventilator-associated tracheobronchitis.
Prevention and treatment of VAT 335setting.23 Last all subjects included in a case-control study
by Nseir et al.7 were also included in an observational cohort
by the same authors, representing 5% of the total pop-
ulation,10 while subjects in another case-control study by
Nseir et al.8 were recruited during the same time period with
the previous two studies.7,10 However,we deliberately chose
to consider these reports7,8 for our review, since their design
(case control studies) offers valuable insights to VAT clinical
course and outcome.
In conclusion, we believe that the findings of the present
systematic review, albeit not without limitations, are of
clinical interest. VAT affects almost one tenth of the
mechanically ventilated patients. Pseudomonas aerugi-
nosa, Acinetobacter spp and methicilin-resistant Staphy-
lococcus aureus, the established culprits of VAP, are also
implicated in VAT pathogenesis. Antimicrobial treatment of
VAT, although it may not reduce mortality rate, it can avert
progression to VAP and improve weaning outcome. Further
prospective studies are warranted to establish reliable
tools for VAT clinical diagnosis and microbiologic confir-
mation and also to evaluate the impact of VAT, its
prevention and its treatment on the outcome of critically ill
patients.
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